CMS专业储备人才笔试试卷.doc

“专业储备人才”笔试试卷 深圳市康哲药业有限公司 适用范围：校园招聘研究生群体 文件编号：hr-zp-010 版本：1.0专业储备人才 笔试试卷V.1.0一英译中： （现场测试：20分钟）Ursodeoxycholic Acid in Cholestatic Liver Disease:Mechanisms of Action and Therapeutic Use RevisitedUrsodeoxycholic acid (UDCA) is increasingly used for the treatment of cholestatic liver diseases. Experimental evidence suggests three major mechanisms of action: (1) protection of cholangiocytes against cytotoxicity of hydrophobic bile acids, resulting from modulation of the composition of mixed phospholipid-rich micelles, reduction of bile acid cytotoxicity of bile and, possibly, decrease of the concentration of hydrophobic bile acids in the cholangiocytes; (2) (3) protection of hepatocytes against bile acidinduced apoptosis, involving inhibition of mitochondrial membrane permeability transition (MMPT), and possibly, stimulation of a survival pathway. In primary biliary cirrhosis, UDCA (13-15 mg/kg/d) improves serum liver chemistries, may delay disease progression to severe fibrosis or cirrhosis, and may prolong transplant-free survival. In primary sclerosing cholangitis, UDCA (13-20 mg/kg/d) improves serum liver chemistries and surrogate markers of prognosis, but effects on disease progression must be further evaluated. Anticholestatic effects of UDCA have also been reported in intrahepatic cholestasis of pregnancy, liver disease of cystic fibrosis, progressive familial intrahepatic cholestasis, and chronic graft-versus-host disease. Future efforts will focus on definition of additional clinical uses of UDCA, on optimized dosage regimens, as well as on further elucidation of mechanisms of action of UDCA at the molecular level. (HEPATOLOGY 2002;36:525-531.)斜体字体部分的注解：ursodeoxycholic acid 熊去氧胆酸 cholestatic 胆汁淤积性 cholangiocytes 胆管细胞 hydrophobic 疏水性phospholipids 磷脂 canalicular 微管 apoptosis （细胞）凋亡 mitochondrial 线粒体的surrogate 替代品 graft-versus-host 移植物抗宿主primary sclerosing cholangitis 原发性硬化性胆管炎二简答题：（限期内邮件回复答卷，建议每题在1000字内）I 基于目前你对处方药营销推广模式和运作的理解，从推广理念、推广模式、推广手段、以及核心竞争优势等方面，阐述处方药“专业化学术推广”和“商业手段推广（即带金销售）”之主要区别；II 在处方药领域成为一名合格的从事“专业化学术推广”工作的推广经理，需要具备哪些必备胜任素质（可提出五项）？为什么？三论述题：（限期内邮件回复答卷，建议每题在2000字内）“优思弗”是康哲药业多年独家代理推广的